{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:29:43Z","timestamp":1791127783511,"version":"4.1.0"},"reference-count":87,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Angiotensin-converting enzyme (ACE) inhibitors are used primarily in the treatment of hypertension, heart failure, and in the acute phase of myocardial infarction. Lisinopril [N2-[(1S)-1-car-boxy-3-phenylpropyl]-L-lysyl-L-proline], enalapril [(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline] and ramipril [2-aza-bicyclo-[3.3.0]-octane-3-carboxylic acid] are all five-membered heterocycles and three of the most prevalent ACE inhibitors in clinical use worldwide. ACE inhibitor-induced angioedema (AE) is clinically characterized by self-limited edema of the dermis and subcutaneous lipid tissue, localized on face skin, oral mucosa and tongue in most cases. However, severe episodes of intestinal AE misdiagnosed as acute appendicitis and laryngeal AE requiring incubation have been reported. The pathophysiology of ACE inhibitor-induced angioedema is attributed to the accumulation of bradykinin, which is a potent vasodilator with proinflammatory activity that is normally degraded by angiotensin-converting enzyme (ACE) and aminopeptidase P; however, a small proportion of treated patients is affected. Given that patients do not respond to anti-H1 antihistamines and steroids, early clinical recognition and discontinuation of the ACE inhibitors are the treatments of choice for the long-term management of ACE inhibitor- induced angioedema. The search period of the present review was set up until November 2023, and its aim is to shed light on the broader context of ACE inhibitor-induced angioedema, exploring aspects such as clinical presentation, pathophysiology, and therapeutic considerations in this potentially life-threatening condition. The exploration of alternative drug options such as angiotensin II receptor blockers, the potential association of coadministration of DPP-4 inhibitors with ACE inhibitors, the presentation of angioedema and the significant clinical importance of this condition are also discussed. By focusing on the chemical structure of ACE inhibitors, specifically their nitrogen-based heterocycles\u2014an attribute shared by over 880 drugs approved by the FDA within the pharmaceutical industry\u2014this review emphasizes the pivotal role of nitrogen scaffolds in drug design and underscores their relevance in ACE inhibitor pharmacology.<\/jats:p>","DOI":"10.3390\/ph17030360","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:05:30Z","timestamp":1710137130000},"page":"360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Five-Membered Nitrogen Heterocycles Angiotensin-Converting Enzyme (ACE) Inhibitors Induced Angioedema: An Underdiagnosed Condition"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-3089","authenticated-orcid":false,"given":"Niki","family":"Papapostolou","sequence":"first","affiliation":[{"name":"Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital \u2018Attikon\u2019, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-1032","authenticated-orcid":false,"given":"Stamatios","family":"Gregoriou","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, \u201cAndreas Syggros\u201d Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-7486","authenticated-orcid":false,"given":"Alexander","family":"Katoulis","sequence":"additional","affiliation":[{"name":"Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital \u2018Attikon\u2019, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-2380","authenticated-orcid":false,"given":"Michael","family":"Makris","sequence":"additional","affiliation":[{"name":"Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital \u2018Attikon\u2019, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,10]]},"reference":[{"key":"ref_1","first-page":"2947","article-title":"Importance of heterocyclic chemistry: A review","volume":"3","author":"Arora","year":"2012","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44247","DOI":"10.1039\/D0RA09198G","article-title":"Prescribed drugs containing nitrogen heterocycles: An overview","volume":"10","author":"Heravi","year":"2020","journal-title":"RSC Adv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10875-015-0228-3","article-title":"Angioedema Triggered by Medication Blocking the Renin\/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database","volume":"36","author":"Faisant","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink","volume":"82","author":"Mahmoudpour","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"Banerji","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record","volume":"5","author":"Banerji","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.anai.2021.07.028","article-title":"Incidence and risk factors of angiotensin-converting enzyme inhibitor-induced angioedema: A large case-control study","volume":"127","author":"Volcheck","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","article-title":"Vasopeptidase inhibition and angio-oedema","volume":"356","author":"Messerli","year":"2000","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","article-title":"ACE Inhibitor-Induced Angioedema: A Review","volume":"20","author":"Kostis","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2125.1999.00093.x","article-title":"Angioedema due to ACE inhibitors: Increased risk in patients of African origin","volume":"48","author":"Gibbs","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/lary.25821","article-title":"Case-control study evaluating competing risk factors for angioedema in a high-risk population","volume":"126","author":"Kamil","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pds.4260","article-title":"Antihypertensive drug associated angioedema: Effect modification by race\/ethnicity","volume":"26","author":"Reichman","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary Angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.molimm.2010.05.010","article-title":"The plasma bradykinin-forming pathways and its interrelationships with complement","volume":"47","author":"Kaplan","year":"2010","journal-title":"Mol. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1710-1492-7-S1-S9","article-title":"Urticaria and angioedema","volume":"7","author":"Kanani","year":"2011","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.otohns.2007.08.012","article-title":"Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"137","author":"Grant","year":"2007","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jemermed.2015.01.016","article-title":"Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Small Bowel-A Surgical Abdomen Mimic","volume":"48","author":"Bloom","year":"2015","journal-title":"J. Emerg. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5811\/westjem.2019.5.42650","article-title":"Evaluation and Management of Angioedema in the Emergency Department","volume":"20","author":"Long","year":"2019","journal-title":"West. J. Emerg. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/000348940111000906","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: A multicenter review and an algorithm for airway management","volume":"110","author":"Chiu","year":"2001","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1345\/aph.1D458","article-title":"Intermittent visceral edema induced by long-term enalapril administration","volume":"38","author":"Orr","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_25","first-page":"860","article-title":"ACE inhibitor angioedema\u2014A very late presentation","volume":"42","author":"Howarth","year":"2013","journal-title":"Aust. Fam. Physician"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0897190012465990","article-title":"Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril","volume":"26","author":"Norman","year":"2013","journal-title":"J. Pharm. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1503\/cmaj.111387","article-title":"Angioedema associated with the use of angiotensin-converting enzyme inhibitor","volume":"185","author":"Nia","year":"2013","journal-title":"Can. Med. Assoc. J."},{"key":"ref_28","unstructured":"Goyal, A., Cusick, A.S., and Thielemier, B. (2024). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1398-9995.2011.02686.x","article-title":"New topics in bradykinin research","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00011-013-0693-1","article-title":"Bradykinin in health and disease: Proceedings of the Bradykinin Symposium 2012, Berlin 23\u201324 August 2012","volume":"63","author":"Magerl","year":"2014","journal-title":"Inflamm. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema","volume":"26","author":"Byrd","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","article-title":"Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors","volume":"359","author":"Adam","year":"2002","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.102.038067","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin","volume":"303","author":"Molinaro","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41440-023-01491-9","article-title":"Prediction and prevention of ACE-inhibitor-induced angioedema\u2014An unmet clinical need in management of hypertension","volume":"47","author":"Rubin","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","article-title":"Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"20","author":"Lucisano","year":"2010","journal-title":"Pharmacogenet Genom."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10557-017-6733-2","article-title":"The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety","volume":"31","author":"Flaten","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/humu.21579","article-title":"A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema","volume":"32","author":"Carter","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1086\/496899","article-title":"A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors","volume":"77","author":"Duan","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","article-title":"Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema","volume":"51","author":"Byrd","year":"2008","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cpt.1927","article-title":"Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema","volume":"108","author":"Maroteau","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mathey, C.M., Maj, C., Eriksson, N., Krebs, K., Westmeier, J., David, F.S., Koromina, M., Scheer, A.B., Szabo, N., and Wedi, B. (2024). Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus. J. Allergy Clin. Immunol., S0091-6749(23)02457-0.","DOI":"10.1016\/j.jaci.2023.11.921"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"Duerr","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto","year":"2004","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.waojou.2023.100809","article-title":"Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers","volume":"16","author":"Douillard","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-021-08841-w","article-title":"Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema","volume":"61","author":"Maurer","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/imr.12632","article-title":"The role and relevance of mast cells in urticaria","volume":"282","author":"Church","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA\u00b2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/cea.13716","article-title":"Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study","volume":"50","author":"Maurer","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jdv.14221","article-title":"Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria","volume":"31","author":"Maurer","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.iac.2017.03.001","article-title":"Histaminergic Angioedema","volume":"37","author":"Busse","year":"2017","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","article-title":"Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group","volume":"69","author":"Cicardi","year":"2014","journal-title":"Allergy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/cea.13219","article-title":"Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema","volume":"48","author":"Christiansen","year":"2018","journal-title":"Clin. Exp. Allergy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/all.15013","article-title":"Identification of novel biomarkers to distinguish bradykinin-mediated angioedema from mast cell-\/histamine-mediated angioedema","volume":"77","author":"Bindke","year":"2022","journal-title":"Allergy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1067\/mai.2002.121313","article-title":"Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema","volume":"109","author":"Karim","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1081-1206(10)61766-8","article-title":"Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema","volume":"92","author":"Warrier","year":"2004","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"192.e191","DOI":"10.1016\/j.ajem.2016.06.089","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema worsened with fresh frozen plasma","volume":"35","author":"Adebayo","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajem.2012.06.021","article-title":"Bradykinin-mediated angioedema: Factors prompting ED visits","volume":"31","author":"Javaud","year":"2013","journal-title":"Am. J. Emerg. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2010.03.023","article-title":"Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant","volume":"63","author":"Schmidt","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Greve","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaci.2016.09.051","article-title":"Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema","volume":"140","author":"Straka","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaip.2017.03.003","article-title":"Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema","volume":"5","author":"Sinert","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anai.2014.12.007","article-title":"Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department","volume":"114","author":"Bernstein","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.annemergmed.2014.07.014","article-title":"Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: A multicenter, randomized, controlled trial","volume":"65","author":"Lewis","year":"2015","journal-title":"Ann. Emerg. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2013.06.021","article-title":"Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks","volume":"111","author":"Craig","year":"2013","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Rasmussen, E.R., and Bygum, A. (2013). ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate. BMJ Case Rep., 2013.","DOI":"10.1136\/bcr-2013-200652"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ccr3.171","article-title":"Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert\u00ae): About one case and review of the therapeutic arsenal","volume":"3","author":"Lipski","year":"2015","journal-title":"Clin. Case Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"E198","DOI":"10.1002\/lary.25113","article-title":"Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema","volume":"125","author":"Greve","year":"2015","journal-title":"Laryngoscope"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajem.2022.12.001","article-title":"Efficacy of human C1 esterase inhibitor concentrate for treatment of ACE-inhibitor induced angioedema","volume":"64","author":"Strassen","year":"2023","journal-title":"Am. J. Emerg. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12245-017-0141-z","article-title":"Angioedema in the emergency department: A practical guide to differential diagnosis and management","volume":"10","author":"Bernstein","year":"2017","journal-title":"Int. J. Emerg. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1345\/aph.1P630","article-title":"The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"45","author":"Beavers","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1081-1206(10)60288-8","article-title":"Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: A meta-analysis","volume":"101","author":"Haymore","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/joim.12867","article-title":"Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors\u2014A nationwide registry-based cohort study","volume":"285","author":"Rasmussen","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573399813666170214113856","article-title":"Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema\u2014An Overlooked Adverse Drug Reaction?","volume":"14","author":"Scott","year":"2018","journal-title":"Curr. Diabetes Rev."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wu, Q., Jiao, Y., Luo, M., Wang, J., Li, J., Ma, Y., and Liu, C. (2023). Detection of Various Traditional Chinese Medicinal Metabolites as Angiotensin-Converting Enzyme Inhibitors: Molecular Docking, Activity Testing, and Surface Plasmon Resonance Approaches. Molecules, 28.","DOI":"10.3390\/molecules28207131"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"124620","DOI":"10.1016\/j.seppur.2023.124620","article-title":"Highly selective and pH responsive adsorption of ZIF-8 for angiotensin-converting enzyme (ACE) inhibitory active peptides and its mechanism","volume":"324","author":"Yue","year":"2023","journal-title":"Sep. Purif. Technol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"134384","DOI":"10.1016\/j.molstruc.2022.134384","article-title":"Transition metal complexes of imidazole derived Schiff bases: Antioxidant\/anti-inflammatory\/antimicrobial\/enzyme inhibition and cytotoxicity properties","volume":"1274","author":"Krishna","year":"2023","journal-title":"J. Mol. Struct."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ding, Y., Xiu, H., Zhang, Y., Ke, M., Lin, L., Yan, H., Hu, P., Xiao, M., He, X., and Zhang, T. (2023). Learning and Investigation of the Role of Angiotensin-Converting Enzyme in Radiotherapy for Nasopharyngeal Carcinoma. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061581"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/3\/360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:11:40Z","timestamp":1760105500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/3\/360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ph17030360"],"URL":"https:\/\/doi.org\/10.3390\/ph17030360","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,10]]}}}